Prognostic significance of relevant markers of cancer stem cells in colorectal cancer - A meta analysis

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1421-1427

  Fan, Chuan Wen ^a   Wen, Lei ^a   Qiang, Zhong De ^c   Chen, Tie ^b   Zhou, Zong Guang ^a   Mo, Xian Ming ^b   Hu, Jian Kun ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Second Out patient Clinic of Chengdu Military Area   (China)

Author keywords

Cancer stem cells; CD44; CD44v6; Colorectal cancer; Prognosis

Indexed keywords

CD44V6 ANTIGEN; HERMES ANTIGEN;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; COCHRANE LIBRARY; COLORECTAL CANCER; CORRELATION ANALYSIS; EMBASE; HUMAN; MEDLINE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD44; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM GRADING; NEOPLASTIC STEM CELLS; ODDS RATIO; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865183460     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10727     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Cunningham D, Atkin W, Lenz HJ, et al.: Colorectal cancer. Lancet 2010; 375:1030-1047.
3. Todaro M, Alea MP, Di Stefano AB, et al.: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1:389-402.
4. Emmink BL, Van Houdt WJ, Vries RG, et al.: Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 2011; 141:269-278.
5. Dylla SJ, Beviglia L, Park IK, et al.: Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3:e2428.
6. Boman BM, Huang E: Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 2008; 26:2828-2838.
7. Rich JN, Bao S: Chemotherapy and cancer stem cells. Cell Stem Cell 2007; 1:353-355.
8. Ong CW, Kim LG, Kong HH, et al.: CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Modern Pathology 2010; 23:450-457.
9. Huh JW, Kim HR, Kim YJ, et al.: Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 2009; 59:241-246.
10. Horst D, Kriegl L, Engel J, et al.: Prognostic Significance of the Cancer Stem Cell Markers CD133, CD44, and CD166 in Colorectal Cancer. Cancer Invest 2009; 27:844-850.
11. Nagata T, Sakakura C, Komiyama S, et al.: Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res 2011; 31:495-500.
12. Fang DD, Kim YJ, Lee CN, et al.: Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer 2010; 102:1265-1275.
13. Penumatsa K, Edassery SL, Barua A, et al.: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res 2010; 3:28.
14. Haraguchi N, Ohkuma M, Sakashita H, et al.: CD133(+) CD44(+) population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008; 15:2927-2933.
15. O'Brien CA, Pollett A, Gallinger S, et al.: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-110.
16. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al.: Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111-115.
17. Du L, Wang H, He L, et al.: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008; 14:6751-6760.
18. Haraguchi N, Ohkuma M, Sakashita H, et al.: CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008; 15:2927-2933.
19. Dalerba P, Dylla SJ, Park IK, et al.: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sd USA 2007; 104:10158-10163.
20. Moller P, Eichelmann A, Mechtersheimer G, et al.: Expression of beta 1-integrins, H-CAM (CD44) and LECAM-1 in primary gastro-intestinal B-cell lymphomas as compared to the adhesion receptor profile of the gut-associated lymphoid system, tonsil and peripheral lymph node. Int J Cancer 1991; 49:846-855.
21. East JA, Hart IR: CD44 and its role in tumour progression and metastasis. Eur J Cancer 1993; 29A:1921-1922.
22. Thomas L: [CD44, the hyaluronic acid cell receptor. Its role in neoplastic invasion and metastatic dissemination]. Bull Cancer 1993; 80:833-844.
23. Herrlich P, Pals S, Ponta H: CD44 in colon cancer. Eur J Cancer 1995; 31A:1110-1112.
24. Orzechowskl HD, Beckenbach C, Herbst H, et al.: Expression of CD44v6 is associated with cellular dysplasia in colorectal epithelial cells. Eur J Cancer 1995; 31A:2073-2079.
25. Fox SB, Fawcett J, Jackson DG, et al.: Normal human tissues, in addition to some tumors, express multiple different CD44 iso-forms. Cancer Res 1994; 54:4539-4546.
26. Coppola D, Hyacinthe M, Fu L, et al.: CD44V6 expression in human colorectal carcinoma. Hum Pathol 1998; 29:627-635.
27. Rodriguez C, Monges G, Rouanet P, et al.: CD44 expression patterns in breast and colon tumors: a PCR-based study of splice variants. Int J Cancer 1995; 64:347-354.
28. Yang YM, Chang JW: Bladder cancer initiating cells (BCICs) are among EMA(-)CD44v6(+) subset: Novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Investigation 2008; 26:725-733.
29. Jijiwa M, Demir H, Gupta S, et al.: CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 2011; 6:e24217.
30. Jansen RH, Joosten-Achjanie SR, Arends JW, et al.: CD44v6 is not a prognostic factor in primary breast cancer. Ann Oncol 1998;9:109-111.
31. Peng J, Lu JJ, Zhu J, et al.: Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer. Cancer J 2008; 14:54-61.
32. Zavrides HN, Zizi-Sermpetzoglou A, Panousopoulos D, et al.: Prognostic evaluation of CD44 expression in correlation with bcl-2 and p53 in colorectal cancer. Folia Histochem Cytobiol 2005; 43:31-36.
33. Horst D, Kriegl L, Engel J, et al.: Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009; 27:844-850.
34. Lugli A, Iezzi G, Hostettler I, et al.: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010; 103:382-390.
35. Mulder JW, Kruyt PM, Sewnath M, et al.: Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994; 344:1470-1472.
36. Koretz K, Moller P, Lehnert T, et al.: Effect of CD44v6 on survival in colorectal carcinoma. Lancet 1995; 345:327-328.
37. Wielenga VJ, van der Voort R, Mulder JW, et al.: CD44 splice variants as prognostic markers in colorectal cancer. Scand J Gastroenterol 1998; 33:82-87.
38. Higgins JP, Thompson SG, Deeks JJ, et al.: Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
39. Bhatavdekar JM, Patel DD, Chikhlikar PR, et al.: Over expression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol 1998; 5:495-501.
40. Ropponen KM, Eskelinen MJ, Lipponen PK, et al.: Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 1998; 33:301-309.
41. Fernandez JC, Vizoso FJ, Corte MD, et al.: CD44s expression in resectable colorectal carcinomas and surrounding mucosa. Cancer Invest 2004; 22:878-885.
42. Ngan CY, Yamamoto H, Seshimo I, et al.: A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol 2007; 95:652-662.
43. Nihei Z, Ichikawa W, Kojima K, et al.: The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surgery Today 1996; 26:760-761.
44. Yamane N, Tsujitani S, Makino M, et al.: Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer. Oncology 1999; 56:232-238.
45. Nanashima A, Yamaguchi H, Sawai T, et al.: Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumor biological factors. Dig Dis Sci 2001; 46:1623-1628.
46. Jungling B, Menges M, Goebel R, et al.: Expression of CD44v6 has no prognostic value in patients with colorectal cancer. Z Gastroenterol 2002; 40:229-233.
47. Barrett LE, Granot Z, Coker C, et al.: Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 2012; 21:11-24.
48. Kobel M, Weichert W, Cruwell K, et al.: Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch 2004; 445:456-464.